The Effect of Rifaximin on Portal Vein Thrombosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

96 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-03

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the efficacy of rifaximin in the treatment of portal vein thrombosis in cirrhotic patients

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis

NCT05863364

Decompensated Cirrhosis

RECRUITING NA

Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis

NCT03193502

Portal Vein Thrombosis

UNKNOWN PHASE3

Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices

NCT02508623

Liver Cirrhosis Portal Hypertension

UNKNOWN PHASE3

Efficacy and Safety of Rifaximin in Treating MAFLD

NCT07185932

Metabolic-associated Fatty Liver Disease

RECRUITING EARLY_PHASE1

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

NCT05621005

Ascites Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Portal vein thrombosis is not an uncommon complication in cirrhotic portal hypertension, which lead to a poor prognosis in endoscopic management of variceal bleeding. Evidence indicated that enoxaparin prevented PVT and liver decompensation via decreased rates of bacterial infections and lowered the potent inflammatory mediators such as interleukin-6. Rifaximin is a broad-spectrum antibiotic that exerts endotoxin-lowering and anti-inflammatory effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cirrhosis Portal Vein Thrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rifaximin treatment group

Rifaximin 400mg bid for 8 weeks

Group Type EXPERIMENTAL

Rifaximin

Intervention Type DRUG

400mg bid for 8 weeks

The control group

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rifaximin

400mg bid for 8 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

XIFAXAN

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 y.o. ≤age≤75 y.o
* Cirrhotic patients had CTA confirmed portal vein trombosis
* D-dimer no more than five times the normal upper limit

Exclusion Criteria

* age \<18 y.o. or age \> 75 y.o.
* had portal cavernoma
* received anticoagulation treatment in the past 6 months
* splenectomy
* Known infection after endoscopic treatment (Fever, microbial cultures positive, et al.)
* Massive ascites or combined with other high risk factor that require prophylaxis use of antibiotics.
* Acute variceal bleeding within 5 days.
* Use of other antibiotics in the past 2 weeks
* Acute portal vein thrombosis

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No